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Nearly two decades ago, researchers first reported that endocrine disrupting chemicals in the environment were
affecting reproductive health in the general population. The purpose of this article is to examine the evidence of
adverse reproductive health trends in Israel and to explore implications for environmental health policy in Israel. We
reviewed studies and data in Israel regarding trends in reproductive health indices, specifically: breast and testis
cancer, hypospadias, sperm quality, male factor infertility, and age at menarche. The data provide some evidence of
adverse reproductive trends in the Israeli population: an increase in testicular cancer from 1990 to 2007, a decrease
in age at menarche from 1986 to 2000, an increase in the prevalence of male factor infertility, and some evidence
of decreasing sperm counts. However, we note that much of the evidence is limited.
The policy implications of reported adverse reproductive health trends possibly related to environmental exposure
have been radically different in Europe and the United States. In Europe, such reports led the Parliament of the
European Community to adopt a resolution on endocrine disruptors, which emphasizes the application of the
Precautionary Principle. U.S. Environmental Protection Agency policy is focused on screening chemicals for
endocrine disrupting properties and does not specifically refer to the Precautionary Principle. To date, there has
been no formal governmental policy or strategy in Israel regarding endocrine disrupting chemicals. Environmental
health policy on endocrine disruptors requires integrating evidence on human reproductive health trends, evidence
on adverse reproductive outcomes in wildlife and experimental systems, and data from biomonitoring studies.
Despite gaps in evidence and current data, we support a precautionary approach to regulating potential endocrine
disrupting chemicals and reducing public exposures, especially in sensitive groups such as children and pregnant
women.
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Nearly two decades ago, researchers first reported that
endocrine disrupting chemicals (EDCs) were affecting
reproductive health, citing evidence from experimental
animal studies, investigations of wildlife populations,
reports on increased incidence of certain pathologies in
men and women, and adverse health outcomes in girls
whose mothers were treated with the estrogenic drug di-
ethylstilbestrol (DES) [1]. The recognition that early em-
bryonic, fetal, or neonatal exposures to EDCs could lead
to permanent health effects in adulthood was central to
the claim that these chemicals were affecting reproduct-
ive health.* Correspondence: tamar.berman@moh.health.gov.il
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reproduction in any medium, provided the orThe group of compounds identified as endocrine
disruptors is highly heterogeneous and includes, for ex-
ample, industrial solvents/lubricants and their bypro-
ducts (e.g., polychlorinated biphenyls, dioxins), plastics
(e.g., bisphenol A (BPA)), plasticizers (e.g., phthalates),
pesticides (e.g., dichlorodiphenyltrichloroethane), fungi-
cides (e.g., vinclozolin), pharmaceutical agents (e.g., DES),
and natural chemicals found in human and animal food
(e.g., phytoestrogens, including genistein and coumes-
trol) [2].
While the evidence for adverse reproductive outcomes
(infertility, congenital malformations, and hormone-
mediated cancers) from exposure to EDCs is strong [2],
it is unclear whether exposures to these chemicals have
impacted reproductive health in the general population
in Israel.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.ijhpr.org/content/1/1/34In 2002, Israel had the highest rate of in vitro
fertilization (IVF) cycles out of 53 countries participating
in the World Collaborative Report on Assisted Repro-
ductive Technology [3]. Data from the Department of
Health Information at the Ministry of Health show that
the rate of IVF treatment cycles including ICSI (per
100,000 women age 15–49) has increased in Israel from
45.5 in 1990 to 154.5 in 2007. Clearly, it is difficult to as-
certain how much of the increasing demand for IVF
treatments in Israel is attributable to economic and so-
cial factors (including state funding of fertility treat-
ments) and how much is attributable to infertility
influenced by other factors, including environmental
exposures.
The purpose of this integrative article is to establish
whether there is evidence of adverse reproductive health
trends in Israel and to explore implications for environ-
mental health policy in Israel. The first part of the paper
will characterize Israeli databases containing data rele-
vant to reproductive health trends in the Israeli popula-
tion and will summarize trends in breast and testis
cancer, hypospadias, male factor infertility, sperm qual-
ity, and age at menarche. The second part of the paper
will explore the environmental health policy implications
of these trends: How have the European Commission
and the U.S. Environmental Protection Agency (EPA)
responded to indications of adverse reproductive health
trends in the population? What is the appropriate health
policy response in Israel to possible adverse reproductive
health trends?
Part 1: Reproductive health trends in Israel
We identified the following Israeli databases as contain-
ing data relevant to reproductive health trends in the Is-
raeli population (Table 1). In this review, we present
data from the international literature, Ministry of Health
publications, conference reports, and unpublished
results.
Cancer
Based on data from the Ministry of Health National
Cancer Registry, which includes an estimated 94% of
solid tumors and 85% of nonsolid tumors, age adjusted
testicular cancer rates in Israel more than doubled in
Jews and Arabs during 1990–2007, with age adjusted
rates twice as high in Jews as in Arabs (Figure 1) [4].
Changes in incidence rates during this period were
prominent in the Northern Negev, perhaps due to differ-
ences in environmental exposures [5].
A recent study of a cohort of military service candi-
dates examined between 1967 and 2005, and linked to
the Israel National Cancer Registry to obtain incident
testicular cancer up to 2006, found lower risk for testicu-
lar cancer among men born in North Africa and Asiacompared to European ancestry, but a steep increase in
risk among next generations of migrants from North
Africa. This study supports further research on the role of
modern lifestyle and environment in the etiology of tes-
ticular cancer (Levine H et al., unpublished manuscript).
In situ breast cancer incidence has increased in both
Jewish and Arab women from 1990 to 2007 (110% in-
crease in Jewish women and 150% increase in Arab
women) [6]. The increase since 1996 can be explained
primarily by the increase in periodic mammography in
the population (the National Mammography Program
began in 1996). Invasive breast cancer incidence
increased in Jewish women between the early 1990s and
1998 and then decreased steadily until 2007. Total breast
cancer rates have been steady since 1998, as the decrease
in invasive breast cancer rates in Jewish women has been
matched by an increase in in situ breast cancer rates. In
Arab women, invasive breast cancer rates more than
tripled between 1990 and 2006, possibly due to improved
diagnosis and socioeconomic changes in the population
during that time (i.e., nutrition, number of births).
Hypospadias
Data from the Israel Birth Defects Registry, which
includes reports on an estimated 70% of total birth
defects in Israel, shows that hypospadias incidence rates
in Israel were unstable between 1974 and 2008 [7].
Overall there was a very small increase during this
period (31.73 per 100,000 in 1974–78 and 33.4 per
100,000 in 2004–2008). Rates of undescended testes in
2000–2008 have also been unstable [8]. It is unclear if
the instability in reported hypospadias and undescended
testes rates is due to data incompleteness or whether it
reflects a real fluctuation in rates of these birth defects
in the population.
Male factor infertility
In 1977, Dor and others reported on 655 infertile cou-























Figure 1 Age Standardized Rate of Testicular Cancer in Israel, 1980–2007. Reproduced from Bar-Chana [4].
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Farhi and Ben-Haroush reported in 2011 that male fac-
tor infertility was the most common cause of infertility
in 2515 couples referred to two infertility clinics in Israel
between 1999 and 2007 [10]. The distributions of the
causes of infertility were male factor infertility (45%),
anovulation (37%), unexplained factors (20.7%), com-
bined factors (18%), and tubal factors (18%), with each
couple having one or more diagnosis. According to Farhi
and Ben-Haroush, there has been a nearly twofold in-
crease in the incidence of male factor infertility in simi-
lar infertile populations attending primary infertility
centers evaluated 30 years apart in Israel [10]. Sella and
others corroborated the finding that male factor infertil-
ity was the most common cause of infertility in a larger
population and reported that male factor infertility was
responsible for 48.80% of cases in 29,282 female mem-
bers of Maccabi Health Services with definitive diagno-
ses of infertility between 1997 and 2010 [11].
Sperm quality
There have been few studies on trends in sperm quality
in Israel. Almagor et al. showed a significant downward
trend in sperm count and motility in Jerusalem men
providing sperm samples for intrauterine insemination
treatment during the years 1990–1999 [12]. Sperm
counts declined by 5.2 ± 0.9 million sperm per year
(p < .0001) and motility was reduced by 0.50 ± 0.14% per
year (p < .0003). This trend remained strongly significant
when men with normal parameters were evaluated sep-
arately, in order to control for the increase in oligoa-
zoospermic patients in later years. In a longitudinal
analysis, where each man’s earliest semen sample was
compared to his latest one, a decrease in sperm countswas observed (decrease of 5.3 ± 4.5 million each year) al-
though results were not significant.
Results of studies in sperm donors in Israel have been
conflicting. One study, published in 1997, found an in-
crease in total motile sperm count (7.74% per year,
p < 0.0001) and a decline in normal morphology in
semen from young Jerusalem donors between 1980 and
1995 (1.04% per year, p < 0.0001) [13]. The study was
conducted in 188 men who donated sperm at the
Hadassah Ein Kerem Hospital. Another study conducted
at the Hadassah Mount Scopus Hospital compared 20
past donors (1995–1999) to 16 interim donors (2000–
2003), and 22 recent donors (2004–2009) [14]. Over the
study period, the average sperm parameters dropped
from a concentration of 106 ± 25 million spermatozoa/
ml with 79%± 4.3% motility to 68 ± 14 million/ml with
66%± 4.5% motile sperm (P < 0.0001, P < 0.0001, respect-
ively). The total motile sperm count per ejaculate also
decreased, from 66.4 ± 18.2 million to 48.7 ± 12 million
(P < 0.005).
Age at menarche
A population-based survey among female recruits to the
Israeli army from 1986 to 2000 found a decrease in age
at menarche, unadjusted for BMI [15]. Reported mean
age at menarche among the 11,392 recruits showed a
monotonic trend of decrease over time, from 13.4 years
for women born before 1970 to 13.0 years for those born
after 1978 (Figure 2). Women born after 1978 were
twice as likely as those born before 1970 to have had an
early menarche (age 11 or earlier). Also, regression mod-
eling showed a negative association between the
recruit’s year of birth and their age at menarche, indicat-














Figure 2 Age at menarche in female recruits to the Israeli army, by birth year. Reproduced from Chodick et al. [15].
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women of western and eastern origins and for all cat-
egories of paternal education. These results likely reflect
the Jewish young adult population in Israel, as military
service is compulsory, with the exception of Arabs and
ultra-Orthodox Jews who are largely exempted from
military service.
Summary of reproductive health trends
The data presented in the first part of this paper provide
some evidence of adverse reproductive trends in the Is-
raeli population: an increase in testicular cancer from
1990 to 2007, an increase in the prevalence of male fac-
tor infertility, a significant decrease in age at menarche
in female recruits to the Israeli army from 1986 to 2000,
and limited evidence of decreasing sperm counts.
However, we note that much of the evidence is limited.
While the increase in testicular cancer in 1990–2007 is
salient, additional types of cancer not associated with
endocrine disruptors have increased in Israel during this
time period. Data on changes in sperm quality in Israeli
sperm donors is valuable, but such studies are inherently
limited by the small sample sizes and the fact that sperm
donors are not representative of the general population.
The studies conducted by Dor and Farhi and Ben-
Haroush on male factor infertility focused on specific
clinics, which might introduce a certain selection bias;
therefore it is unclear if the upward trend in male factor
infertility reflects a national trend. In addition, it is pos-
sible that technological advances in diagnosis affected
the difference in incidence of male factor infertility
reported in 1977 and in 2011. Data on age at menarche
in female recruits were unadjusted for BMI, and it is un-
clear if changes in obesity and life style during this
period or other factors explain this trend.In addition, other factors that are potentially related to
reproductive health trends in Israel have changed in the
population over the period that these adverse reproduct-
ive health trends were observed: increased recreational
drug use [16]; a steep rise in obesity and overweight in
youth [17]; major demographic shifts resulting from im-
migration trends [18]; and widespread soy consumption
[personal communication], including soy based formula
[19]. Increased recreational drug use, for example, may
contribute to the increased prevalence in male factor in-
fertility [20], while trends in prevalence of overweight
may contribute to trends in age at menarche [21].
Despite the limitations in the data, the fact that ad-
verse reproductive health trends have been reported in
other populations worldwide suggests that there is some
plausibility to the hypothesis that these trends are indeed
occurring in Israel. Testicular cancer has been increasing
worldwide in the majority of industrialized countries in
North America, Europe, and Oceania, particularly
among Caucasians [22]. In several European countries,
including France, testicular cancer incidence has
doubled since 1970 [23]. In addition, studies from Euro-
pean and U.S. populations indicate a trend toward
younger ages of menarche and breast development in
girls [24,25]. Finally, meta-analyses have indicated a de-
cline in mean sperm concentrations since the 1930s
[26,27] although these analyses have been challenged
[28]. In Denmark, sperm counts in healthy young men
are so low that researchers have predicted lower fertility
rates in the future [29].
Part II: Environmental health policy implications
Endocrine Disrupting Chemicals: EU and U.S. Policy
Initiatives and Responses: The policy implications of
reported adverse reproductive health trends possibly
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different in Europe and the U.S.
In 1996 scientists and policy-makers in Europe con-
vened the Weybridge Workshop and reached the con-
clusion that “sufficient evidence exists for increasing
testicular cancer rates, and the apparent decline in
sperm counts in some areas was unlikely to be attribut-
able to the known confounding variables.” Despite the
fact that they concluded that existing exposure informa-
tion was generally insufficient to definitely associate the
human changes seen with chemical exposure, they noted
that measures to reduce exposure to endocrine disrup-
ters should be in line with the Precautionary Principle
[30].
The EU Community Strategy for Endocrine Disrup-
ters, which was adopted in 1998, emphasizes the applica-
tion of the Precautionary Principle and calls on the
Commission to identify substances for immediate action
[31]. Actions that have been carried out by the Commis-
sion in relation to EDCs have included: a) development
of a priority list of potential endocrine disrupting sub-
stances; b) monitoring studies, including a European
wide biomonitoring study on phthalates in urine; c) re-
search; and d) legislative actions such as restrictions on
approval of EDCs for plant protection, legislation on
food contact materials, including banning the use of
BPA in infant feeding bottles, and new legislation on
phthalates in toys [32].
In the U.S., the Endocrine Disruptor Screening Pro-
gram Policy Statement from 1998 cited “conflicting
reports . . . concerning declines in the quality and
quantity of sperm production in humans over the last
4 decades, and . . . reported increases in certain can-
cers (e.g., breast, prostate, testicular)” but added that
there is “considerable scientific uncertainty . . . regard-
ing the actual causes of such effects.” [33] The U.S.
Congress passed the Food Quality Protection Act and
the Safe Drinking Water Act Amendments in 1996, re-
quiring that the EPA screen chemicals and pesticides
for their potential to produce effects similar to those
produced by estrogen in humans. The EPA later
expanded the screening program to include androgens
and the thyroid system, and to include effects on fish
and wildlife.
According to these acts, if a substance is found “to
have an endocrine effect on humans, the Administrator
shall . . . take action under such statutory authority as is
available to the Administrator . . . as is necessary to en-
sure the protection of public health.” In other words, the
statutes requiring testing for endocrine disruption pro-
vide no new process by which to regulate those chemi-
cals. In addition, this approach demands scientifically
proving harm in humans prior to regulating a chemical,
without addressing the uncertainty involved in endocrinedisruption and without mention of the Precautionary
Principle [34].
Additional policy actions in the U.S. related to poten-
tial endocrine disruptors have included banning the use
of phthalates in toys [35] and “taking reasonable steps
to reduce human exposure to BPA in the food supply”
[36].
Implications for Environmental Health Policy in Israel:
In both the EU and the U.S., evidence regarding adverse
reproductive health trends in the general population was
considered when developing environmental health policy
on EDCs. However, this data was considered within the
broader context of evidence on the impact of EDCs on
wildlife and experimental systems. To date, there has
been no formal governmental policy or strategy in Israel
regarding EDCs. Current actions in Israel have focused
on three main aspects: monitoring, research/surveillance,
and policy/legislation.
Monitoring
In the U.S., there is on-going surveillance of population
exposure to environmental chemicals, including estrogen
disrupting chemicals within the framework of the Na-
tional Health and Nutrition Health Survey [37]. This
surveillance supplies valuable data to assess the effective-
ness of public health efforts to reduce exposure to envir-
onmental chemicals, to determine whether exposure
levels are higher among susceptible subgroups, and to
direct priorities for research on human health effects
from exposure to these chemicals. The EU has recently
launched a harmonized biomonitoring study on expos-
ure to methyl mercury, cadmium, and phthalates, as well
as environmental tobacco.
In Israel, the Ministry of Health recently conducted
the first national biomonitoring study to measure expo-
sures to BPA, phthalates, organophosphates, polyaro-
matic hydrocarbons, the phytoestrogens genistein and
daidzein, and cotinine in the Israeli adult population
[38]. The study involved collection of urine samples
from 250 adults in Israel, with detailed demographic and
dietary data, including a 24-hour recall and food fre-
quency questionnaire. Data on urinary concentrations of
environmental contaminants in the study participants
indicate widespread exposure to environmental chemi-
cals, including to synthetic and natural endocrine dis-
rupting compounds. Further study will include analyses
of predictors of exposure (intake of food items/use of
consumer products), data that will aid in assessing pos-
sible sources of exposure and can be used to develop
policy actions to reduce population exposure to these
environmental chemicals. The Ministry of Health is also
currently conducting a study on levels of persistent or-
ganic pollutants, including dioxins, in pooled breast milk
samples.
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Currently, there is lack of surveillance on reproductive
health outcomes for the Israeli population. We
emphasize the need for further study in Israel on repro-
ductive health trends and on possible associations be-
tween adverse reproductive outcomes and exposures to
environmental chemicals. Researchers at the Hebrew
University of Jerusalem have recently initiated studies on
associations between organophosphate exposure and
endocrine outcomes related to male infertility, and on
associations between prenatal exposure to phthalates
and BPA and birth outcomes. We note that endocrine
disrupting chemicals may interfere with endocrine sys-
tems other than the reproductive system and emphasize
the need for study on trends of thyroid conditions, obes-
ity, and diabetes and possible associations with exposure
to environmental chemicals. We also note that many
epidemiological studies on the associations between
exposures to environmental chemicals and adverse re-
productive outcomes have been hampered by the lack of
individual exposure assessment.
Policy/legislation
The precautionary approach has been applied in Israel
in a number of recent policy decisions concerning EDCs,
including for example the ban on use of BPA in baby
bottles and the decision to severely restrict the use of
the herbicide atrazine. In the case of BPA, quantitative
risk assessments showed that little or negligible risk was
expected following normal use of baby bottles [39,40].
However, since there was considerable uncertainty
regarding the effects of low dose chronic exposure, evi-
dence of increased vulnerability in infants and children,
and available alternatives, the Ministry of Health
adopted a precautionary approach [41].
In addition, the Ministry of Health recently recom-
mended the ban of the herbicides atrazine and simazine
in Israel, based on concerns regarding possible effects on
reproduction and fetal development from chronic low
dose exposure via drinking water. In this case, current
levels of these herbicides in drinking water in Israel are
far below the Israeli Drinking Water Standard, suggest-
ing that there is negligible risk to the population. In fact,
the World Health Organization recently recommended
an increase in the drinking water standard in light of
evidence that atrazine is not carcinogenic in humans.
However, given emerging suggestive evidence of adverse
effects on reproduction and development at very low
levels of exposure, and given that there were available
alternatives, the Ministry of Health adopted a precau-
tionary approach.
We argue that environmental health policy on EDCs
should be informed by a broad range of evidence, in-
cluding data on trends in reproductive health, evidencefrom wildlife and experimental systems, and biomonitor-
ing data.
Despite gaps in evidence and current data regarding
adverse effects of environmental chemicals on repro-
ductive health in Israel, we support a precautionary ap-
proach to regulating EDCs and reducing public
exposures, especially in sensitive groups such as children
and pregnant women. We argue that this principle
should be invoked following a) identification of poten-
tially negative serious or irreversible effects resulting
from a phenomenon, product, or procedure; b) a scien-
tific evaluation of the risk; and c) evaluation of the ex-
tent of the scientific uncertainty [42]. We emphasize
that the Precautionary Principle should be invoked in
cases where scientific uncertainty or insufficiency of the
data, or their inconclusive or imprecise nature, makes it
impossible to determine with sufficient certainty the risk
in question. As Wier et al. have argued, the appropriate-
ness of applying the precautionary principle increases
when the exposure or harm is widespread, when the in-
cidence of the harm (i.e., observed health effect) is in-
creasing and is otherwise unexplained; when the
suspected harm is serious; when the suspected harm is
not easily treatable or reversible; when the economic
and social costs of removing the exposure are small rela-
tive to the suspected harm; when the health costs of re-
moving the exposure are minimal; and when, in addition
to the uncertain harms, there are known health, eco-
nomic, or social harms caused by the exposure [43].
We note also that the public-health strategy for deal-
ing with potential effects of EDCs must reflect governing
national and international legalities. In the international
trade environment in which Israel is obligated to operate
by its treaty obligations (i.e., General Agreement on Tar-
iffs and Trade – Uruguay Round-Non-Tariff Barriers,
Sanitary and Phytosanitary Measures) there are restric-
tions on the ability to apply any measure without scien-
tific justification [44].
In the cases of BPA in baby bottles and atrazine in
drinking water, in-depth scientific evaluation of the po-
tential risk revealed significant uncertainties that made it
impossible to determine that current exposure levels
would result in negligible or no risk to the general popu-
lation. In addition, in both of these cases potential ex-
posure of the general population was widespread and
the potential health outcomes were both serious and ir-
reversible. However, we note the significant challenges
in application and logical consistency of the Precaution-
ary Principle in environmental health policy. For ex-
ample, with regard to food contact uses of BPA, the
Ministry of Health, in light of European and U.S. policy,
has yet to determine whether there is a case for applying
the Precautionary Principle and restricting or banning
this use.
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There is limited evidence of adverse reproductive trends
in the Israeli population. However, relative absence of
evidence regarding adverse effects of environmental ex-
posure on Israeli reproductive health does not equal the
evidence of absence of such a problem. This is especially
true in Israel, where there has been little research on
associations between environmental exposures in the
general population and adverse reproductive outcomes.
We emphasize the importance of applying the Precau-
tionary Principle in environmental health policy, moni-
toring exposure of the population to environmental
chemicals, and monitoring trends in reproductive health
outcomes in Israel. The Ministry of Health is currently
evaluating research and policy development needs.
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